Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000216 | 1.00 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL11677537 | 0.87 | FAAH (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL10329427 | 0.85 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL11678695 | 0.85 | EPHX1 (0.36) | ALDH1A1 | |
| SCHEMBL11679311 | 0.85 | PKM (0.35) | — | |
| SCHEMBL11676740 | 0.84 | — | — | |
| SCHEMBL11676751 | 0.80 | EPHX1 (0.46) | ALDH1A1 | |
| SCHEMBL11676128 | 0.77 | — | — | |
| SCHEMBL11679051 | 0.77 | GAA (0.32) | ALDH1A1 | |
| SCHEMBL11675618 | 0.77 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114436972-B | Pabendazole derivative, and preparation method and application thereof | 山东大学 | 2024-02-13 | — | — | CN | disclosed |
| EP-3298005-B1 | ANTI-CANCER COMPOUNDS | UNIV CALIFORNIA (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3475272-B1 | PHTHALAZINE DERIVATIVES AS INHIBITORS OF PARP1, PARP2 AND/OR TUBULIN USEFUL FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11708352-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-25 | — | — | US | disclosed |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-25 | — | — | US | disclosed |
| CN-114436972-A | Pabendazole derivative and preparation method and application thereof | 山东大学 | 2022-05-06 | — | — | CN | disclosed |
| US-11149025-B2 | Anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-19 | — | — | US | disclosed |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-01-14 | — | — | US | disclosed |
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-05-05 | — | — | US | disclosed |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | SPERO THERAPEUTICS, INC. | 2013-06-20 | — | — | US | disclosed |
| WO-2012177707-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184564-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012097270-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL}-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097273-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL) PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097269-A1 | PYRIMIDINE GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012097274-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATION (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640493-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ALDH1A1 1526/4885SMN1; SMN2 2445/4885 |
| US-20210009562-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | ALDH1A1 793/4885SMN1; SMN2 2063/4885 |
| US-11072600-B2 | Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer | PARP2, PARP12, PARP1 | ALDH1A1 1089/4885SMN1; SMN2 2955/4885 |
| US-11708352-B2 | Anti-cancer compounds | TP53, VHL, BAD | ALDH1A1 793/4885SMN1; SMN2 2063/4885 |
| US-20120184742-A1 | PROCESS OF MAKING GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 3589/4885SMN1; SMN2 4216/4885 |
| US-20220267307-A1 | ANTI-CANCER COMPOUNDS | TP53, VHL, BAD | ALDH1A1 793/4885SMN1; SMN2 2063/4885 |
| US-20130157979-A1 | PHOSPHATE ESTERS OF GYRASE AND TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 3745/4885SMN1; SMN2 4637/4885 |
| US-20120184512-A1 | GYRASE AND TOPOISOMERASE IV INHIBITORS | TOP1, TOP2A, TOP2B | ALDH1A1 2840/4885SMN1; SMN2 3597/4885 |
| US-11149025-B2 | Anti-cancer compounds | TP53, VHL, BAD | ALDH1A1 793/4885SMN1; SMN2 2063/4885 |
| US-20120184564-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[6-FLUORO-5-[2-(1-HYDROXY-1-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALDH1A1 2070/4885SMN1; SMN2 3253/4885 |
| US-20120184741-A1 | SOLID FORMS OF GYRASE INHIBITOR (R)-1-ETHYL-3-[5-[2-(1-HYDROXY-METHYL-ETHYL)PYRIMIDIN-5-YL]-7-(TETRAHYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA | TOP1, TOP2A, TOP2B | ALDH1A1 2926/4885SMN1; SMN2 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.